EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

Gerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F Azevedo, Derek Coombs, Ivan Lagunes, Ralph Lippe, Peter Wung, Lianne S Gensler

Rheumatology and Therapy · 2024-06 · 11 (3) · 737-753

DOI: 10.1007/s40744-024-00671-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 29.04.2024. Verfasst von Gerd R Burmester und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany. Gerd.Burmester@charit…. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AdalimumabAnkylosing spondylitisJAK inhibitorNon-radiographic axial spondyloarthritisPsoriatic arthritisSafetyUpadacitinib

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany. Gerd.Burmester@charite.de.
  • AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.
  • Division of Rheumatology, Cantonal Clinic St Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Sankt Gallen, Switzerland.
  • The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 1-1, Iseigaoka, Kitakyushu, 807-8555, Japan.
  • Rheumatology Unit, Hospital de Clínicas, Federal University of Paraná, Rua General Carneiro 181, Curitiba, Paraná, 80000-000, Brazil.
  • Department of Medicine/Rheumatology, University of California San Francisco, 400 Parnassus Ave B1, San Francisco, CA, 94143, USA.

Förderung

  • AbbVie

Zitieren

APA

Burmester, G. R., Stigler, J., Rubbert-Roth, A., Tanaka, Y., Azevedo, V. F., Coombs, D., Lagunes, I., Lippe, R., Wung, P., & Gensler, L. S. (2024). Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatology and Therapy, 11(3), 737-753. https://doi.org/10.1007/s40744-024-00671-4

Vancouver

Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, et al. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatology and Therapy. 2024;11(3):737-753. doi:10.1007/s40744-024-00671-4

BibTeX
@article{Burmester2024,
  author = {Burmester, Gerd R and Stigler, Jayne and Rubbert-Roth, Andrea and Tanaka, Yoshiya and Azevedo, Valderilio F and Coombs, Derek and Lagunes, Ivan and Lippe, Ralph and Wung, Peter and Gensler, Lianne S},
  title = {Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials},
  journal = {Rheumatology and Therapy},
  year = {2024},
  volume = {11},
  number = {3},
  pages = {737--753},
  doi = {10.1007/s40744-024-00671-4}
}
Kostenlos starten →